Diagnostics and devices play stronger hand at Chugai Pharmaceutical
This article was originally published in Clinica
Chugai Pharmaceutical (Japan) has reported an 11.3% rise in diagnostics sales in 1994. Turnover in the division reached ¥,900 million ($91 million), says the company, and was led by sales of DNA probes and enzyme-immunoassay diagnostic systems. Chugai launched its DNA probe for tuberculosis diagnosis in May 1994.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.